A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg
or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed
Bonviva study BM16549 (MOBILE study). Patients will receive Bonviva either 100mg po monthly,
or 150mg po monthly. Patients will also receive daily supplementation with vitamin D and
calcium. The anticipated time of study treatment is 2+ years, and the target sample size is
500+ individuals.